These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16638345)

  • 21. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
    Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
    Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
    Chen ZH; Zhao J; Wu JM; Xiao CG
    Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.
    Bratslavsky G; Fisher HA; Kaufman RP; Voskoboynik D; Nazeer T; Mian BM
    Urol Oncol; 2008; 26(2):166-70. PubMed ID: 18312936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease].
    Zhang P; Wang ZM; Chong T; Zhao LH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):871-3, 903. PubMed ID: 17953381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    J Urol; 1997 Feb; 157(2):544-7. PubMed ID: 8996352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
    Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of clinically significant prostate cancer by prostate-specific antigen screening.
    Smith RP; Malkowicz SB; Whittington R; VanArsdalen K; Tochner Z; Wein AJ
    Arch Intern Med; 2004 Jun; 164(11):1227-30. PubMed ID: 15197049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Finne P; Auvinen A; Määttänen L; Tammela TL; Ruutu M; Juusela H; Martikainen P; Hakama M; Stenman UH
    Eur Urol; 2008 Aug; 54(2):362-70. PubMed ID: 18006214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
    J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
    Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
    Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.